title: Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs.
abstract: A serum hemagglutination inhibition (HAI) titer of 40 or greater is thought to be associated with reduced influenza virus pathogenesis in humans and is often used as a correlate of protection in influenza vaccine studies. We have previously demonstrated that intramuscular vaccination of guinea pigs with inactivated influenza virus generates HAI titers greater than 300 but does not protect vaccinated animals from becoming infected with influenza virus by transmission from an infected cage mate. Only guinea pigs intranasally inoculated with a live influenza virus or a live attenuated virus vaccine, prior to challenge, were protected from transmission (A. C. Lowen et al., J. Virol. 83:2803-2818, 2009.). Because the serum HAI titer is mostly determined by IgG content, these results led us to speculate that prevention of viral transmission may require IgA antibodies or cellular immune responses. To evaluate this hypothesis, guinea pigs and ferrets were administered a potent, neutralizing mouse IgG monoclonal antibody, 30D1 (Ms 30D1 IgG), against the A/California/04/2009 (H1N1) virus hemagglutinin and exposed to respiratory droplets from animals infected with this virus. Even though HAI titers were greater than 160 1 day postadministration, Ms 30D1 IgG did not prevent airborne transmission to passively immunized recipient animals. In contrast, intramuscular administration of recombinant 30D1 IgA (Ms 30D1 IgA) prevented transmission to 88% of recipient guinea pigs, and Ms 30D1 IgA was detected in animal nasal washes. Ms 30D1 IgG administered intranasally also prevented transmission, suggesting the importance of mucosal immunity in preventing influenza virus transmission. Collectively, our data indicate that IgG antibodies may prevent pathogenesis associated with influenza virus infection but do not protect from virus infection by airborne transmission, while IgA antibodies are more important for preventing transmission of influenza viruses.
authors.affiliation: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
authors.forename: Christopher W
authors.initials: CW
authors.lastname: Seibert
authors.forename: Saad
authors.initials: S
authors.lastname: Rahmat
authors.forename: Jens C
authors.initials: JC
authors.lastname: Krause
authors.forename: Dirk
authors.initials: D
authors.lastname: Eggink
authors.forename: Randy A
authors.initials: RA
authors.lastname: Albrecht
authors.forename: Peter H
authors.initials: PH
authors.lastname: Goff
authors.forename: Florian
authors.initials: F
authors.lastname: Krammer
authors.forename: J Andrew
authors.initials: JA
authors.lastname: Duty
authors.forename: Nicole M
authors.initials: NM
authors.lastname: Bouvier
authors.forename: Adolfo
authors.initials: A
authors.lastname: García-Sastre
authors.forename: Peter
authors.initials: P
authors.lastname: Palese
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D057134:Antibodies, Neutralizing / Q000008:administration & dosage; D001483:Base Sequence; D003001:Cloning, Molecular; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D005289:Ferrets; D006168:Guinea Pigs; D057809:HEK293 Cells; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology* / Q000494:pharmacology; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000235:genetics; D053118:Influenza A Virus, H1N1 Subtype; D061985:Madin Darby Canine Kidney Cells; D051379:Mice; D008969:Molecular Sequence Data; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission*; D011994:Recombinant Proteins / Q000276:immunology* / Q000494:pharmacology; D017422:Sequence Analysis, DNA
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D011994:Recombinant Proteins